114 related articles for article (PubMed ID: 27567865)
1. Stimulating the Activity of Amyloid-Beta Degrading Enzymes: A Novel Approach for the Therapeutic Manipulation of Amyloid-Beta Levels.
Kuruppu S; Rajapakse NW; Spicer AJ; Parkington HC; Smith AI
J Alzheimers Dis; 2016 Oct; 54(3):891-895. PubMed ID: 27567865
[TBL] [Abstract][Full Text] [Related]
2. Powering Amyloid Beta Degrading Enzymes: A Possible Therapy for Alzheimer's Disease.
Sikanyika NL; Parkington HC; Smith AI; Kuruppu S
Neurochem Res; 2019 Jun; 44(6):1289-1296. PubMed ID: 30806879
[TBL] [Abstract][Full Text] [Related]
3. Regulation of amyloid beta-peptide levels by enzymatic degradation.
Mukherjee A; Hersh LB
J Alzheimers Dis; 2002 Oct; 4(5):341-8. PubMed ID: 12446966
[TBL] [Abstract][Full Text] [Related]
4. Understanding molecular mechanisms of proteolysis in Alzheimer's disease: progress toward therapeutic interventions.
Higuchi M; Iwata N; Saido TC
Biochim Biophys Acta; 2005 Aug; 1751(1):60-7. PubMed ID: 16054018
[TBL] [Abstract][Full Text] [Related]
5. Effect of Tong Luo Jiu Nao on Aβ-degrading enzymes in AD rat brains.
Liu Y; Hua Q; Lei H; Li P
J Ethnopharmacol; 2011 Sep; 137(2):1035-46. PubMed ID: 21798326
[TBL] [Abstract][Full Text] [Related]
6. Impact of Insulin Degrading Enzyme and Neprilysin in Alzheimer's Disease Biology: Characterization of Putative Cognates for Therapeutic Applications.
Jha NK; Jha SK; Kumar D; Kejriwal N; Sharma R; Ambasta RK; Kumar P
J Alzheimers Dis; 2015; 48(4):891-917. PubMed ID: 26444774
[TBL] [Abstract][Full Text] [Related]
7. Design of Peptide Substrate for Sensitively and Specifically Detecting Two Aβ-Degrading Enzymes: Neprilysin and Angiotensin-Converting Enzyme.
Chen PT; Chen CL; Lin LT; Lo CH; Hu CJ; Chen RP; Wang SS
PLoS One; 2016; 11(4):e0153360. PubMed ID: 27096746
[TBL] [Abstract][Full Text] [Related]
8. Aβ-degrading enzymes: potential for treatment of Alzheimer disease.
Miners JS; Barua N; Kehoe PG; Gill S; Love S
J Neuropathol Exp Neurol; 2011 Nov; 70(11):944-59. PubMed ID: 22002425
[TBL] [Abstract][Full Text] [Related]
9. 4-O-methylhonokiol attenuated memory impairment through modulation of oxidative damage of enzymes involving amyloid-β generation and accumulation in a mouse model of Alzheimer's disease.
Choi IS; Lee YJ; Choi DY; Lee YK; Lee YH; Kim KH; Kim YH; Jeon YH; Kim EH; Han SB; Jung JK; Yun YP; Oh KW; Hwang DY; Hong JT
J Alzheimers Dis; 2011; 27(1):127-41. PubMed ID: 21799245
[TBL] [Abstract][Full Text] [Related]
10. Amyloid-degrading enzymes as therapeutic targets in Alzheimer's disease.
Nalivaeva NN; Fisk LR; Belyaev ND; Turner AJ
Curr Alzheimer Res; 2008 Apr; 5(2):212-24. PubMed ID: 18393806
[TBL] [Abstract][Full Text] [Related]
11. Endothelin-converting enzymes and related metalloproteases in Alzheimer's disease.
Pacheco-Quinto J; Herdt A; Eckman CB; Eckman EA
J Alzheimers Dis; 2013; 33 Suppl 1(0 1):S101-10. PubMed ID: 22903130
[TBL] [Abstract][Full Text] [Related]
12. Amyloid beta degradation: a challenging task for brain peptidases.
Morelli L; Bulloj A; Leal MC; Castaño EM
Subcell Biochem; 2005; 38():129-45. PubMed ID: 15709476
[TBL] [Abstract][Full Text] [Related]
13. Peptidases, proteases and amyloid beta-peptide catabolism.
Hersh LB
Curr Pharm Des; 2003; 9(6):449-54. PubMed ID: 12570808
[TBL] [Abstract][Full Text] [Related]
14. BIIB042, a novel γ-secretase modulator, reduces amyloidogenic Aβ isoforms in primates and rodents and plaque pathology in a mouse model of Alzheimer's disease.
Scannevin RH; Chollate S; Brennan MS; Snodgrass-Belt PA; Peng H; Xu L; Jung MY; Bussiere T; Arastu MF; Talreja T; Xin Z; Dunstan RW; Fahrer D; Rohde E; Dunah AW; Wang J; Kumaravel G; Taveras AG; Moore Arnold H; Rhodes KJ
Neuropharmacology; 2016 Apr; 103():57-68. PubMed ID: 26690893
[TBL] [Abstract][Full Text] [Related]
15. Neprilysin deficiency alters the neuropathological and behavioral phenotype in the 5XFAD mouse model of Alzheimer's disease.
Hüttenrauch M; Baches S; Gerth J; Bayer TA; Weggen S; Wirths O
J Alzheimers Dis; 2015; 44(4):1291-302. PubMed ID: 25408216
[TBL] [Abstract][Full Text] [Related]
16. Activation of Ras-ERK Signaling and GSK-3 by Amyloid Precursor Protein and Amyloid Beta Facilitates Neurodegeneration in Alzheimer's Disease.
Kirouac L; Rajic AJ; Cribbs DH; Padmanabhan J
eNeuro; 2017; 4(2):. PubMed ID: 28374012
[TBL] [Abstract][Full Text] [Related]
17. Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease.
Rockenstein E; Torrance M; Mante M; Adame A; Paulino A; Rose JB; Crews L; Moessler H; Masliah E
J Neurosci Res; 2006 May; 83(7):1252-61. PubMed ID: 16511867
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin-converting enzyme as a potential target for treatment of Alzheimer's disease: inhibition or activation?
Zou K; Michikawa M
Rev Neurosci; 2008; 19(4-5):203-12. PubMed ID: 19145983
[TBL] [Abstract][Full Text] [Related]
19. Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease.
Hemming ML; Patterson M; Reske-Nielsen C; Lin L; Isacson O; Selkoe DJ
PLoS Med; 2007 Aug; 4(8):e262. PubMed ID: 17760499
[TBL] [Abstract][Full Text] [Related]
20. Impacts of aging and amyloid-β deposition on plasminogen activators and plasminogen activator inhibitor-1 in the Tg2576 mouse model of Alzheimer's disease.
Bi Oh S; Suh N; Kim I; Lee JY
Brain Res; 2015 Feb; 1597():159-67. PubMed ID: 25454795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
